Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB021 plus exemestane in hormone receptor-positive advanced metastatic breast cancer after nonsteroidal aromatase inhibitor progression
2009-014796-51Phase 2Completed
- Sponsor
- Biogen
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of biib021 and exemestane in breast cancer (2 arms), sponsored by Biogen. Primary endpoint: progression-free survival. Started Nov 2009; status: completed.
02
Drugs
biib021exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-014796-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014796-51.